UNSPSC 51401603: Tiapride

This classification denotes an anti-dyskinesia agent, antipsychotic agent, and dopamine antagonist with the molecular formula C15H24N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LAH70H9JPH, chemically known as benzamide, n-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)- but generally known as tiapride, which bears US NIH Compound Identifier 5467. European Medicines Agency schedules Tiapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11010MIG.

UNSPSC 51401603 Tiapride is a Commodity code that in practice covers pharmaceutical products and related health commodities procured by state and local health agencies, though the recent solicitations under this code reflect a broader pharmaceutical supply landscape than tiapride alone. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent solicitations for naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription programs. State health departments and county health agencies dominate the issuing body mix, with multistate cooperative purchasing vehicles like MMCAP extending reach across participating jurisdictions including Minnesota and Oregon. Scope spans both emergency-response pharmaceuticals (naloxone) and routine pharmaceutical supply for health facilities and state employee programs, with vendors typically required to certify compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, FDA requirements, maintain specified insurance coverages, and demonstrate EDI capability or electronic procurement system access.

Recent activity clusters in Florida and the Upper Midwest. Seminole County's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; vendors must comply with E-Verify and drug-free workplace certification, with contracts potentially funded through FEMA. MMCAP's S1070000015802, posted January 20, 2026 with responses due March 26, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products across state and local facilities, with evaluation weighted heavily toward price competitiveness (75 percent) and requiring vendors to maintain relationships with authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson. The Texas HHS RFI HHS0017013, posted April 3, 2026, represents exploratory procurement—seeking vendor information on direct-to-manufacturer prescription fulfillment rather than a formal bid, signaling the state's intent to gather market intelligence before issuing a formal RFP.